Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.14)
# 1,102
Out of 5,182 analysts
6
Total ratings
60%
Success rate
131.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.84 | +18.44% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $4 | $0.58 | +589.54% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $5.47 | -8.59% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $14.50 | +65.52% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $1.92 | +212.50% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.61 | +2,045.21% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.84
Upside: +18.44%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $4
Current: $0.58
Upside: +589.54%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $5.47
Upside: -8.59%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $14.50
Upside: +65.52%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.92
Upside: +212.50%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.61
Upside: +2,045.21%